ライフサイエンスコーパス: bone sarcoma

1 kade of NGF reduced weight loss in mice with bone sarcoma.

2 therapy in the treatment of soft tissue and bone sarcoma.

3 anti-angiogenesis agents in soft tissue and bone sarcoma.

4 als with DMS develop MFH, a highly malignant bone sarcoma.

5 oarthritis, rheumatoid arthritis and primary bone sarcoma.

6 atients with advanced soft-tissue sarcoma or bone sarcoma.

7 D-based gene therapy affected soft tissue or bone sarcomas.

8 the prediction of survival before therapy in bone sarcomas.

9 e, which is the most common site for primary bone sarcomas.

10 nd outcomes of patients with soft-tissue and bone sarcomas.

11 d drive experiments and trials in metastatic bone sarcomas.

12 Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurabl

13 To identify putative sCSCs, autologous bone sarcoma and STS cells were engineered with a CSC de

14 nduced killer (CIK) cells against autologous bone sarcoma and STS, including against putative sCSCs.

15 However, patients without bone sarcoma and those able to tolerate therapy for more

16 sponse rate was 40% (95% CI, 24% to 56%) for bone sarcomas and 19% (95% CI, 6% to 32%) for soft tissu

17 are changing the diagnosis and treatment of bone sarcomas and carcinomas metastatic to bone.

18 oad applicability for mechanistic studies of bone sarcomas and exhibits the potential to augment prec

19 ese trials, 27 (61%) were male; 18 (41%) had bone sarcoma, and 26 (59%) had soft tissue sarcoma.

20 steoid osteomas, giant-cell lesions of bone, bone sarcomas, and metastases.

21 Soft tissue and bone sarcomas are malignancies of mesenchymal origin, an

22 ed in the osteosarcoma and Ewing's subset of bone sarcomas at nanomolar concentrations of dasatinib.

23 Better understanding of potential bone sarcoma biological subgroups, the role of the tumou

24 In addition, 5FC treatment of bone sarcomas caused a significant reduction in cancer-i

25 lso induced apoptosis, indicating that these bone sarcoma cell lines are dependent on Src activity fo

26 types and selectively blocks the survival of bone sarcoma cells.

27 ed 18 years or older to enrol; patients with bone sarcoma could enrol if they were aged 12 years or o

28 Paediatric bone sarcomas (e.g. Ewing sarcoma, osteosarcoma) compris

29 ation of the molecular mechanisms underlying bone sarcomas, especially in the case of osteogenic sarc

30 Around 70% of patients with bone sarcoma experience metastasis during their disease

31 nrolled patients with soft-tissue sarcoma or bone sarcoma from 12 academic centres in the USA that we

32 d 90% CI 21-43), 19 of 54 in IGF-1R-positive bone sarcoma group (35%; one-sided 95% CI lower bound 24

33 Nine (11%) patients (five [12%] in the bone sarcoma group and four [10%] in the soft-tissue sar

34 arch and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group categories or as absent or present.

35 decreased platelet count (three [7%]) in the bone sarcoma group, and anaemia, decreased lymphocyte co

36 arch and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group, the National Institutes for Health,

37 ft-tissue sarcoma (group A), IGF-1R-positive bone sarcomas (group B), or IGF-1R-negative bone and sof

38 Two (5%) of 40 patients with bone sarcoma had an objective response, including one (5

39 CI, 0.23-0.93; P = .03) and those without a bone sarcoma (ie, neither primitive neuroectodermal tumo

40 Osteosarcoma is the most common bone sarcoma in children and young adults.

41 of which were considered treatment-related; bone sarcoma in cohort 2 and sarcoma in cohort 1).

42 In contrast, body and extremity bone sarcoma incidence flattened after adolescence (3.5%

43 t discoveries in the molecular mechanisms of bone sarcomas may help to elucidate the pathogenesis of

44 med that only a few cases of soft tissue and bone sarcoma metastasis to the locations of primary inte

45 tients either with metastatic soft-tissue or bone sarcoma (n = 6) or with pancreatic cancer (n = 3) w

46 Soft tissue and bone sarcomas of the extremities can be difficult to era

47 entify a gene involved in the development of bone sarcoma, provide evidence of the primate-specific e

48 ), AML (RR = 11.2; 95% CI, 2.1 to 61.2), and bone sarcoma (RR = 7.3; 95% CI, 2.0 to 26.2) were at hig

49 onstituting a broad range of soft tissue and bone sarcoma subtypes across the entire age spectrum.

50 s of girls with metastases of soft tissue or bone sarcomas to the reproductive system or breasts are

51 Using a mouse graft model of bone sarcoma, we demonstrate that early treatment with a

52 Bone sarcomas were eliminated in 9 of 10 5FC-treated mic

53 Patients with metastatic soft tissue or bone sarcomas who achieved objective response or stable

54 management of patients with soft tissue and bone sarcomas will be discussed.

55 nd, in patients with advanced soft tissue or bone sarcoma with progressive disease.

56 ade 2 or higher or ungradable soft-tissue or bone sarcoma, with negative or equivocal findings for no